Released on: November 13, 2007, 12:07 pm

Press Release Author: InvestorIdeas.com

Industry: Financial

Press Release Summary: China-AsiaStocks.com Reports on Listings from Shanghai to
Hong Kong to U.S. Markets,
Updating Growing Stock Directory for Investors Following Sector

Press Release Body: POINT ROBERTS, Wash., Delta B.C., November 13, 2007 -
InvestorIdeas.com and China-AsiaStocks.com, its investor and industry portal focused
on the China-Asia sector, updates its growing stock directory with new public
company listings as investors witness the China IPO frenzy and seek investment
opportunities in the sector. From Shanghai's listing of oil and gas conglomerate,
PetroChina- China\'s largest domestic IPO, to the recent Alibaba.com IPO on the Hong
Kong stock exchange, the market can't fill the growing appetite for China related
listings.

According to a recent report by Ernst & Young, companies in mainland China and Hong
Kong raised $14.3 billion in the third quarter and the number of company listings in
Hong Kong and mainland China hit new records. Philip Leung commented in their
release "The record number of IPO's shows that companies were quick to react to keen
investor interest in equities ".

Outside of American Depositary Shares (ADS), investors can also invest in the China
play in the micro cap markets. After Market Support, LLC, a wholly owned subsidiary
of Keating Investments, is a financial marketing firm specializing in creating
liquidity for publicly traded stocks and has worked with multiple clients that have
gone public through reverse mergers (a method of going public increasingly replacing
IPOs for micro cap issuers). Keating has an office and division in Shanghai
(www.keatingasia.com) According to Justin Davis of After Market Support, LLC.,
currently working with Benda Pharmaceutical, Inc., (OTCBB: BPMA), smaller listed
companies can provide investors the opportunity to get in on the ground floor of
China's dramatic growth story. Justin does advise investors to complete their own
due diligence and review SEC filings prior to investing.

"To become a Keating reverse merger client like Benda Pharmaceutical, a Chinese
company must first pass muster through a rigorous and multi-layered due diligence
process. Keating begins with an overall analysis of the industry, market
opportunity, the company's relative competitiveness and growth potential. If a
company clears immediate hurdles, Keating then drills deeper into business,
financial and legal due diligence, conducting multiple site visits and contracting
independent, professionally-executed background checks. Finally, each company must
have in place a management team that understands the business of being a U.S. public
company. Many firms do not stand up to this level of scrutiny. Those that remain
resemble Benda - already profitable, Benda has tremendous growth potential via
Gendicine®, the first gene therapy drug for the treatment of cancer on the market,
anywhere in the world."

Benda Pharmaceutical (OTCBB: BPMA) is building its presence within the fast
growing Chinese market and beyond, forecasting that Gendicine® will generate $16
million in revenue in 2008, up from estimates of $6.2 million for 2007. In total,
the Company anticipates revenues to reach $25.1 million in 2007 and progressing
upwards to $56.7 million in 2008.

Yahoo!s (NASDAQ: YHOO) US$1 billion investment (40% interest) in Alibaba's
business-to-business trading portal, represents another alternative for U.S.
investors looking to participate in and own shares in companies doing business in
China .

Some notable recent and pending China listing market debuts include- Longtop\'s
(NYSE:LFT) American Depositary Shares, posting significant gains its first day of
trading Longtop, provides information technologies services to China\'s financial
services sector.

Also making headlines- China National Heavy Duty Truck Co, a heavy truck maker, in
a Hong Kong IPO and Giant Interactive Group Inc ADSs (NYSE: GA), an online game
developer .
In the pipeline is AirMedia, planning to list its ADSs on NASDAQ, trading symbol AMCN.

FUQI International, Inc. (NASDAQ: FUQI) recent IPO at $9.00 has already had a range
of $6.50 - $11.75 and is currently down from its IPO debut. FUQI International, Inc.
designs high quality precious metal jewelry in China.

For investors researching the sector Investor Ideas China -Asia portal offers a
growing directory of listed stocks as a reference tool. Visit:
http://www.investorideas.com/Companies/China-AsiaStocks/Stocks_List.asp

Benda Pharmaceutical Inc. is a Showcase Company on Investor Ideas. Compensation is
disclosed in disclaimer below.
Visit: http://www.investorideas.com/co/bpma/
Additional Benda Pharmaceutical Inc Investor Resources
Fact Sheet:
http://files.shareholder.com/downloads/BPMA/151228937x4452657x111082/95430c49-a77a-43c9-89ad-d6cc75cffc59/FactSheet.pdf

PowerPoint Presentation:
http://files.shareholder.com/downloads/BPMA/151228937x4452657x111087/35a10e95-f328-45ad-81ab-529f6cc1af6d/Bendapresentation061107.pdf

Gendicine Video:
http://play.rbn.com/play.asx?url=shareholder/shareholder/wmdemand/bendavideo.wmv&proto=mms?mswmext=.asx
* To read the full Ernst & Young China IPO report:
http://www.ey.com/Global/assets.nsf/China_E/1007_IPO_PR_Eng/$file/IPO_Press%20Release_Eng_HK.pdf

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal
specialized in sector investing covering over thirty industry sectors and global
markets including China, India, Middle East and Australia.

InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp. Our sites
do not make recommendations, but offer information portals .Nothing on our sites
should be construed as an offer or solicitation to buy or sell products or
securities.. All Information relating to featured companies is sourced from public
documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by featured companies, news submissions and online
advertising. Benda Pharmaceutical, Inc. (OTCBB: BPMA) $4000USD per month.

For More Information Contact:
Dawn Van Zant 800-665-0411 Email: dvanzant@investorideas.com

Web Site: www.InvestorIdeas.com
Source: China-AsiaStocks.com, Benda Pharmaceutical, Inc.




Web Site: http://www.china-asiastocks.com

Contact Details: Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com